Bisoprolol Vitabalans: Uses, Dosage & Side Effects
A cardioselective beta-1 blocker used for the treatment of hypertension (high blood pressure) and stable chronic heart failure
Bisoprolol Vitabalans is a prescription medication containing bisoprolol fumarate, a highly selective beta-1 adrenergic receptor blocker (cardioselective beta-blocker). It is primarily used for the treatment of hypertension (high blood pressure) and stable chronic heart failure. Bisoprolol works by slowing the heart rate, reducing the force of cardiac contractions, and lowering blood pressure, thereby decreasing the overall workload on the heart. Available as 5 mg film-coated tablets for once-daily oral administration, bisoprolol has been extensively studied in landmark clinical trials including CIBIS-II and CIBIS-III, demonstrating significant mortality reduction in heart failure patients. It is one of the most widely prescribed beta-blockers worldwide.
Quick Facts: Bisoprolol Vitabalans
Key Takeaways
- Bisoprolol Vitabalans is a cardioselective beta-1 blocker primarily prescribed for hypertension and stable chronic heart failure, with proven mortality benefits demonstrated in the landmark CIBIS-II trial.
- The medication is taken once daily in the morning, with or without food, and must never be stopped abruptly as sudden withdrawal can cause dangerous rebound tachycardia, worsening angina, or in rare cases, myocardial infarction.
- At therapeutic doses, bisoprolol is highly selective for beta-1 receptors in the heart, meaning it has minimal effects on the airways, making it one of the safer beta-blocker options for patients with mild asthma or COPD, though caution is still required.
- Common side effects include fatigue, dizziness, cold extremities, and bradycardia; patients with diabetes should be aware that bisoprolol can mask hypoglycemic symptoms, particularly tachycardia.
- For heart failure, treatment must be initiated at a very low dose (1.25 mg) and titrated slowly upward under medical supervision, as starting at full dose can worsen heart failure symptoms.
What Is Bisoprolol Vitabalans and What Is It Used For?
Bisoprolol Vitabalans belongs to a class of medications known as beta-adrenergic blocking agents, or more commonly, beta-blockers. Specifically, bisoprolol is classified as a beta-1 selective (cardioselective) blocker, which means it preferentially acts on the beta-1 adrenergic receptors found predominantly in the heart, rather than the beta-2 receptors found in the lungs, blood vessels, and other tissues. This selectivity is clinically important because it allows bisoprolol to exert its cardiac effects while minimizing the respiratory side effects (such as bronchospasm) that can occur with non-selective beta-blockers.
The mechanism of action of bisoprolol involves competitive antagonism of catecholamines (adrenaline and noradrenaline) at the beta-1 adrenergic receptors in the heart. Under normal conditions, catecholamines bind to these receptors and stimulate the heart to beat faster and with greater force. By blocking these receptors, bisoprolol reduces the heart rate (negative chronotropic effect), decreases the force of cardiac contraction (negative inotropic effect), slows conduction through the atrioventricular (AV) node (negative dromotropic effect), and decreases myocardial oxygen consumption. The net result is a lower heart rate, reduced cardiac output, and decreased blood pressure.
In the context of hypertension, bisoprolol lowers blood pressure through several interconnected mechanisms. The reduction in cardiac output is the primary mechanism, but bisoprolol also reduces renin release from the kidneys (renin is an enzyme that initiates a hormonal cascade leading to vasoconstriction and sodium retention), resets baroreceptor sensitivity, and may reduce central sympathetic outflow. The antihypertensive effect develops gradually, with the full therapeutic benefit typically observed after 1 to 2 weeks of consistent use. According to the European Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines, beta-blockers including bisoprolol remain a recommended first-line treatment option for hypertension, particularly in patients with compelling indications such as heart failure, post-myocardial infarction, or rate control in atrial fibrillation.
For the treatment of stable chronic heart failure, bisoprolol has a robust evidence base. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a landmark randomized controlled trial published in The Lancet in 1999, demonstrated that bisoprolol significantly reduced all-cause mortality by 34% in patients with moderate to severe heart failure (NYHA class III–IV) when added to standard therapy with ACE inhibitors and diuretics. The study was stopped early due to the clear survival benefit. The subsequent CIBIS-III trial showed that bisoprolol could be used as initial therapy before an ACE inhibitor in heart failure patients. Based on this evidence, bisoprolol is one of four beta-blockers specifically recommended in the ESC and AHA/ACC heart failure guidelines (alongside carvedilol, metoprolol succinate, and nebivolol).
Bisoprolol is also used for the management of stable angina pectoris, where it reduces the frequency and severity of anginal episodes by lowering myocardial oxygen demand. By reducing heart rate and contractility, bisoprolol ensures that the heart requires less oxygen during exertion, thereby reducing the threshold at which ischemia-related chest pain occurs. Additionally, bisoprolol may be prescribed off-label for rate control in atrial fibrillation or atrial flutter, management of certain arrhythmias, prevention of migraine, and management of some anxiety-related symptoms such as performance anxiety (though this is a non-standard use).
The cardioselectivity of bisoprolol means it has approximately 14 times greater affinity for beta-1 receptors (found mainly in the heart) than for beta-2 receptors (found in the lungs and blood vessels). However, this selectivity is dose-dependent and diminishes at higher doses. At doses above 20 mg daily, bisoprolol may also block beta-2 receptors, potentially causing bronchospasm in susceptible individuals. Even at lower doses, caution is advised in patients with severe asthma or severe COPD.
What Should You Know Before Taking Bisoprolol Vitabalans?
Contraindications
Bisoprolol must not be taken in the following situations, as it could cause serious harm or worsen existing conditions:
- Hypersensitivity: Allergy to bisoprolol fumarate or any of the excipients in the tablet formulation.
- Acute or decompensated heart failure: Bisoprolol is indicated for stable chronic heart failure, not acute decompensation requiring intravenous inotropic support. Starting or increasing bisoprolol during an episode of worsening heart failure can be dangerous.
- Cardiogenic shock: A condition in which the heart cannot pump enough blood to meet the body’s needs. Beta-blockers further reduce cardiac output and are contraindicated.
- Second- or third-degree atrioventricular (AV) block: Without a functioning pacemaker, bisoprolol can dangerously slow or stop electrical conduction through the heart.
- Sick sinus syndrome: A group of heart rhythm problems caused by malfunction of the sinus node (the heart’s natural pacemaker), unless a permanent pacemaker is in place.
- Sinoatrial block: A type of heart block involving the sinus node.
- Severe bradycardia: A resting heart rate below 50 beats per minute before treatment begins. Bisoprolol would further slow the heart rate.
- Severe hypotension: Systolic blood pressure below 90 mmHg. Bisoprolol lowers blood pressure and could cause dangerous falls in blood pressure.
- Severe bronchial asthma or severe COPD: Beta-blockade, even with cardioselective agents, carries a risk of bronchospasm in patients with severe obstructive airway disease.
- Late stages of peripheral arterial occlusive disease or Raynaud’s syndrome: Beta-blockers can worsen peripheral circulation problems.
- Untreated pheochromocytoma: A rare adrenal gland tumor that produces excess catecholamines. Beta-blockade without prior alpha-blockade can cause a hypertensive crisis.
- Metabolic acidosis: An acid-base imbalance in the blood that can be worsened by beta-blockers.
Warnings and Precautions
Never stop taking bisoprolol abruptly without consulting your doctor. Sudden withdrawal of beta-blockers can cause rebound tachycardia (rapid heart rate), severe hypertension, worsening angina, and in rare cases, myocardial infarction or sudden death, particularly in patients with ischemic heart disease. If discontinuation is necessary, the dose should be reduced gradually over at least 1 to 2 weeks under medical supervision.
Special caution is required and your doctor should be informed if any of the following conditions apply:
- Diabetes mellitus: Bisoprolol can mask the symptoms of hypoglycemia (low blood sugar), particularly tachycardia, tremor, and anxiety. Sweating as a symptom of hypoglycemia is generally not masked. Patients with diabetes should monitor their blood glucose levels more frequently, and insulin or oral hypoglycemic drug doses may need adjustment.
- Thyrotoxicosis (overactive thyroid): Beta-blockers can mask the signs and symptoms of hyperthyroidism, particularly tachycardia. Abrupt withdrawal may precipitate a thyroid storm.
- Strict fasting: Bisoprolol may mask symptoms of hypoglycemia during periods of fasting.
- First-degree AV block: Bisoprolol slows conduction through the AV node and could worsen pre-existing first-degree block to a higher degree.
- Prinzmetal’s angina (variant angina): There have been reports that beta-blockers may increase the number and duration of anginal attacks in patients with vasospastic angina. Use with caution.
- Mild to moderate bronchial asthma or COPD: Although bisoprolol is cardioselective, caution is still necessary. A bronchodilator should be available, and the lowest effective dose should be used. Respiratory function should be monitored.
- Peripheral arterial disease: Beta-blockers may aggravate symptoms of peripheral circulatory disorders, including intermittent claudication.
- General anesthesia: If you are scheduled for surgery, inform your anesthesiologist that you are taking bisoprolol. The drug’s effects on the heart may interact with anesthetic agents. In most cases, bisoprolol should be continued during the perioperative period, but the anesthesiologist needs to be aware to manage heart rate and blood pressure appropriately.
- Psoriasis: Beta-blockers have been reported to worsen or trigger psoriasis. Use with caution in patients with a history of psoriasis.
- Pheochromocytoma: In patients with a known pheochromocytoma, bisoprolol should only be used after adequate alpha-receptor blockade has been established.
Pregnancy and Breastfeeding
Bisoprolol is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. Beta-blockers can reduce placental blood flow, which may result in intrauterine growth retardation, intrauterine death, miscarriage, or premature labor. Additionally, the newborn infant may experience adverse effects including hypoglycemia, bradycardia, respiratory depression, and hypothermia. If treatment with bisoprolol is considered essential during pregnancy, uteroplacental blood flow and fetal growth should be monitored closely. The newborn should be carefully monitored after delivery, as symptoms of hypoglycemia and bradycardia may occur within the first 48 to 72 hours. Alternative antihypertensive agents such as labetalol or methyldopa are generally preferred during pregnancy according to international guidelines.
It is not known whether bisoprolol is excreted in human breast milk. However, other beta-blockers have been detected in breast milk, and therefore breastfeeding is not recommended during treatment with bisoprolol. If breastfeeding is desired, discuss alternative medications with your doctor.
Driving and Operating Machinery
Bisoprolol may cause dizziness, fatigue, or visual disturbances, particularly at the start of treatment, when the dose is increased, or when combined with alcohol. These effects can impair your ability to drive or operate machinery. Assess your individual response to the medication before engaging in activities that require alertness and coordination. If you experience these symptoms, avoid driving or operating machinery until they have resolved.
How Does Bisoprolol Vitabalans Interact with Other Drugs?
Drug interactions with bisoprolol can be broadly categorized into those that enhance its cardiac depressant effects (additive bradycardia, hypotension, or AV block), those that alter its blood pressure-lowering effects, and those where bisoprolol masks important clinical signs. Understanding these interactions is essential for safe use. Always provide your doctor and pharmacist with a complete list of all medications, supplements, and herbal products you are taking.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Verapamil, Diltiazem (non-dihydropyridine calcium channel blockers) | Additive negative effects on heart rate, AV conduction, and contractility; risk of severe bradycardia, heart block, and heart failure | Avoid intravenous verapamil/diltiazem with bisoprolol; oral combination requires close monitoring |
| Clonidine | If clonidine is withdrawn while still taking bisoprolol, severe rebound hypertension can occur; additive bradycardia when used together | If both must be discontinued, stop bisoprolol several days before gradually withdrawing clonidine |
| Amiodarone, Dronedarone | Additive depression of AV node conduction and sinus node function; risk of severe bradycardia and heart block | Combination requires careful monitoring; dose adjustment of bisoprolol may be necessary |
| Digoxin | Additive slowing of heart rate and AV conduction; increased risk of symptomatic bradycardia | Monitor heart rate closely; both drugs slow AV conduction through different mechanisms |
| Insulin, Sulfonylureas (antidiabetic drugs) | Bisoprolol masks tachycardia (a key warning sign of hypoglycemia); may enhance and prolong hypoglycemic episodes | More frequent blood glucose monitoring required; patient should recognize other hypoglycemia symptoms (sweating, hunger) |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Amlodipine, Nifedipine (dihydropyridine calcium channel blockers) | Additive blood pressure lowering; possible increase in risk of hypotension and heart failure in susceptible patients | Generally safe combination but monitor blood pressure; commonly co-prescribed for hypertension |
| NSAIDs (ibuprofen, naproxen, diclofenac) | NSAIDs may reduce the antihypertensive effect of bisoprolol through sodium and water retention | Monitor blood pressure if NSAIDs are used regularly; consider paracetamol as an alternative analgesic |
| ACE inhibitors, ARBs (e.g., ramipril, losartan) | Additive blood pressure lowering; synergistic benefit in heart failure | Commonly co-prescribed; monitor blood pressure and renal function |
| Anesthetic agents | Enhanced cardiac depressant effects during anesthesia; risk of severe hypotension and bradycardia | Inform anesthesiologist; bisoprolol usually continued perioperatively with appropriate monitoring |
| Mefloquine | Additive bradycardia | Monitor heart rate if co-administered |
| MAO inhibitors (except MAO-B inhibitors) | Theoretically enhanced hypotensive effect; risk of hypertensive crisis is a concern with certain MAOIs | Use with caution; monitor blood pressure carefully |
Bisoprolol has relatively few pharmacokinetic interactions because it is eliminated through both renal and hepatic pathways in approximately equal proportions. It undergoes limited cytochrome P450 metabolism (primarily CYP3A4 and CYP2D6), but to a degree that clinically significant inhibition or induction of these enzymes by other drugs does not substantially alter bisoprolol levels in most cases. However, potent CYP3A4 inhibitors (such as ketoconazole or ritonavir) or CYP2D6 inhibitors may modestly increase bisoprolol plasma levels. The pharmacodynamic interactions listed above are generally more clinically important than pharmacokinetic interactions.
What Is the Correct Dosage of Bisoprolol Vitabalans?
The dose of bisoprolol depends on the condition being treated and must be individualized. Your doctor will determine the appropriate starting dose and any subsequent adjustments based on your response to treatment, heart rate, blood pressure, and any side effects. It is important to take bisoprolol at the same time each day, preferably in the morning, with or without food. Tablets should be swallowed whole with a glass of water and should not be chewed or crushed.
Adults – Hypertension and Angina
Hypertension (High Blood Pressure)
Starting dose: 5 mg once daily
Usual maintenance dose: 5–10 mg once daily
Maximum dose: 20 mg once daily
The dose may be adjusted after 1–2 weeks based on blood pressure response. In some patients, 2.5 mg daily may be sufficient as a starting dose, particularly in elderly patients or those with impaired renal or hepatic function.
Stable Angina Pectoris
Starting dose: 5 mg once daily
Usual maintenance dose: 5–10 mg once daily
Maximum dose: 20 mg once daily
Dose adjustments should be made based on heart rate and clinical response. The goal is to achieve a resting heart rate of 55–60 beats per minute for optimal anti-anginal effect.
Adults – Stable Chronic Heart Failure
Heart Failure (Slow Titration Required)
Treatment must be initiated under close medical supervision. The patient must be on stable standard heart failure therapy (ACE inhibitor or ARB, and diuretics, with or without cardiac glycosides) without recent episodes of decompensation.
Titration schedule:
- Week 1–2: 1.25 mg once daily
- Week 3–4: 2.5 mg once daily
- Week 5–8: 3.75 mg once daily
- Week 9–12: 5 mg once daily
- Week 13–16: 7.5 mg once daily
- Week 17 onward: 10 mg once daily (target maintenance dose)
Each dose increase requires assessment of heart rate, blood pressure, symptoms, and tolerability. If the patient does not tolerate a dose increase, the dose may be reduced or temporarily withheld. In some cases, the maximum tolerated dose may be lower than 10 mg.
Starting bisoprolol at too high a dose in heart failure patients can be dangerous, potentially causing acute worsening of heart failure with fluid retention, hypotension, and bradycardia. The slow dose titration over many weeks is essential to allow the heart to adapt gradually to the protective effects of beta-blockade.
Children and Adolescents
The safety and efficacy of bisoprolol in children and adolescents below 18 years of age have not been established. There is insufficient data to recommend its use in this population, and bisoprolol should not be prescribed to children unless directed by a specialist pediatric cardiologist.
Elderly Patients
No dose adjustment is routinely required for elderly patients. However, as elderly patients are more susceptible to bradycardia, hypotension, and dizziness, treatment should generally be started at the lower end of the dosing range and titrated cautiously. Regular monitoring of heart rate, blood pressure, renal function, and clinical symptoms is recommended.
Renal and Hepatic Impairment
In patients with mild to moderate renal impairment (creatinine clearance above 20 mL/min) or mild to moderate hepatic impairment, no dose adjustment is usually necessary. However, in patients with severe renal impairment (creatinine clearance below 20 mL/min) or severe hepatic impairment, the dose should not exceed 10 mg daily, and dose titration should be performed with particular caution and more frequent monitoring.
Missed Dose
If you forget to take a dose of bisoprolol, take it as soon as you remember on the same day. However, if it is almost time for your next scheduled dose, skip the missed dose entirely and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose, as this could cause an excessive drop in heart rate or blood pressure.
Overdose
In case of a suspected overdose, seek emergency medical attention immediately. Symptoms of bisoprolol overdose may include severe bradycardia (very slow heart rate), severe hypotension (very low blood pressure), bronchospasm (wheezing and difficulty breathing), acute heart failure, and hypoglycemia (low blood sugar). Treatment is supportive and may include intravenous atropine for bradycardia, intravenous fluids and vasopressors for hypotension, glucagon for cardiac depression, and bronchodilators for bronchospasm. In severe cases, temporary cardiac pacing may be necessary.
What Are the Side Effects of Bisoprolol Vitabalans?
Like all medicines, bisoprolol can cause side effects, although not everybody experiences them. Many side effects are dose-related and may be more pronounced at the start of treatment. Your body usually adjusts to the medication over time, and some initial side effects may diminish or disappear after several weeks of continued use. If any side effect becomes severe or persistent, consult your doctor. The side effects listed below are organized by how frequently they occur based on clinical trial data and post-marketing surveillance.
Very Common
May affect more than 1 in 10 people
- Bradycardia (slow heart rate) – especially in heart failure patients
Common
May affect up to 1 in 10 people
- Fatigue, tiredness, and feeling of weakness (asthenia)
- Dizziness and lightheadedness
- Headache
- Cold or numb extremities (cold hands and feet)
- Nausea and vomiting
- Diarrhea or constipation
- Worsening of heart failure symptoms (in heart failure patients during dose titration)
- Hypotension (low blood pressure), particularly postural hypotension
Uncommon
May affect up to 1 in 100 people
- Sleep disturbances, including insomnia and vivid dreams
- Depression or depressed mood
- AV conduction disturbances (heart block)
- Bronchospasm (in patients with asthma or obstructive airway disease)
- Muscle weakness and cramps
- Erectile dysfunction
- Dry mouth
- Elevated liver enzymes (ALT, AST, gamma-GT)
Rare
May affect up to 1 in 1,000 people
- Allergic reactions including rash, itching, and flushing
- Reduced tear flow (may be relevant for contact lens wearers)
- Hearing disturbances
- Allergic rhinitis (runny or stuffy nose)
- Hepatitis (inflammation of the liver)
- Nightmares
- Hallucinations
Not Known
Frequency cannot be estimated from available data
- Syncope (fainting)
- Conjunctivitis (eye inflammation)
- Alopecia (hair loss)
- Worsening of psoriasis or psoriasiform rash
- Beta-blocker withdrawal syndrome (if stopped abruptly)
In clinical trials for heart failure, worsening heart failure symptoms were common during the initial titration phase. This is expected as the heart adapts to beta-blockade and usually improves with continued therapy. Your doctor will monitor you closely during dose titration and may temporarily reduce the dose or pause the up-titration if symptoms worsen significantly. Long-term treatment with bisoprolol ultimately improves heart function and reduces the risk of hospitalization and death.
Beta-blockers as a class have been associated with metabolic effects including increased triglyceride levels and decreased HDL cholesterol, though these effects are generally less pronounced with cardioselective agents like bisoprolol compared with non-selective beta-blockers. The clinical significance of these metabolic effects in the context of the cardiovascular benefits of bisoprolol is considered minor.
Contact your doctor or seek emergency care immediately if you experience any of the following: severe dizziness or fainting, a very slow heart rate (below 50 beats per minute) with symptoms, severe difficulty breathing or wheezing, sudden swelling of the ankles or legs (sign of worsening heart failure), or signs of an allergic reaction (swelling of the face, lips, tongue, or throat).
How Should You Store Bisoprolol Vitabalans?
Proper storage of medications is essential to maintain their effectiveness and safety throughout the product’s shelf life. Bisoprolol Vitabalans tablets should be stored at room temperature, not exceeding 25°C (77°F). Keep the tablets in their original blister packaging or container to protect them from moisture and light exposure. Do not store in the bathroom or other humid environments, as moisture can degrade the tablets.
Keep all medications out of the reach and sight of children. The product should not be used after the expiry date stated on the outer packaging and blister foil. The expiry date refers to the last day of that month. If your tablets have changed color, become discolored, or show any signs of deterioration, do not take them and consult your pharmacist about proper disposal.
Do not dispose of medications via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer need. These measures will help protect the environment and prevent accidental ingestion by others.
What Does Bisoprolol Vitabalans Contain?
The active substance in Bisoprolol Vitabalans is bisoprolol fumarate. Each film-coated tablet contains 5 mg of bisoprolol fumarate, which is equivalent to approximately 4.24 mg of bisoprolol free base. Bisoprolol fumarate is a white crystalline powder that is equally soluble in water and alcohol. Its chemical name is (±)-1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol fumarate (2:1).
The other ingredients (excipients) in the tablet core typically include:
- Microcrystalline cellulose: A commonly used filler and binder that gives the tablet its structural integrity.
- Calcium hydrogen phosphate (dihydrate): Serves as a diluent (filler) to achieve the desired tablet size.
- Croscarmellose sodium: A disintegrant that helps the tablet break apart in the gastrointestinal tract for proper drug release and absorption.
- Colloidal anhydrous silica: A glidant that improves powder flow during manufacturing.
- Magnesium stearate: A lubricant that prevents the tablet mixture from sticking to manufacturing equipment.
The film coating typically contains hypromellose, macrogol, titanium dioxide (E171), and may contain iron oxide yellow (E172) depending on the tablet strength and visual identification requirements. The film coating protects the tablet and makes it easier to swallow.
Bisoprolol Vitabalans 5 mg tablets are film-coated and typically available in blister packs of 30, 60, or 100 tablets. The tablets are scored and may be divided into equal halves to allow flexible dosing when required. Always check the package leaflet for the most current and complete list of ingredients, as formulations may vary between batches and manufacturing updates.
Frequently Asked Questions About Bisoprolol Vitabalans
Bisoprolol Vitabalans is primarily used for two main conditions: hypertension (high blood pressure) and stable chronic heart failure. For hypertension, it works by lowering the heart rate and reducing the force of the heart’s contractions, which in turn lowers blood pressure. For heart failure, when started at a very low dose and slowly increased, it protects the heart from the damaging effects of prolonged activation of the sympathetic nervous system. It may also be used for stable angina pectoris (chest pain from reduced blood flow to the heart) and off-label for rate control in atrial fibrillation.
No, you must never stop taking bisoprolol suddenly without medical supervision. Abrupt withdrawal of beta-blockers can trigger a dangerous rebound effect, including a rapid increase in heart rate, worsening of angina symptoms, and in rare cases, myocardial infarction (heart attack) or sudden cardiac death. This is particularly dangerous in patients with ischemic heart disease. If you and your doctor decide that treatment should be stopped, the dose must be reduced gradually over at least 1 to 2 weeks, with regular monitoring of your heart rate and blood pressure during the tapering period.
Some patients report modest weight gain while taking beta-blockers, including bisoprolol. This may be related to a slight reduction in metabolic rate, reduced exercise tolerance due to lower heart rate, or fluid retention in heart failure patients. However, bisoprolol is generally considered to cause less weight gain compared with some older, non-selective beta-blockers. If you notice significant weight gain, particularly rapid weight gain (more than 2 kg in a few days), this could indicate fluid retention and worsening heart failure, and you should contact your doctor promptly.
Alcohol can enhance the blood pressure-lowering effect of bisoprolol and may increase the risk of dizziness, lightheadedness, and fainting. While moderate alcohol consumption is not absolutely contraindicated, it is advisable to limit alcohol intake and be aware of the potential for enhanced effects. Avoid excessive alcohol consumption, particularly at the start of treatment or when the dose is being adjusted. If you experience dizziness or lightheadedness after drinking alcohol while on bisoprolol, sit or lie down and avoid sudden position changes.
Bisoprolol is a cardioselective beta-blocker, meaning it primarily targets beta-1 receptors in the heart rather than beta-2 receptors in the lungs. This makes it one of the safer beta-blocker choices for patients with mild to moderate asthma or COPD, compared with non-selective beta-blockers. However, cardioselectivity is relative and dose-dependent — at higher doses, bisoprolol may also block beta-2 receptors and cause bronchospasm. Bisoprolol is absolutely contraindicated in severe asthma or severe COPD. For patients with mild to moderate asthma, bisoprolol should only be used if clearly indicated, at the lowest effective dose, and with a bronchodilator readily available. Your doctor will weigh the benefits against the respiratory risks.
Bisoprolol is typically taken once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water. Consistency is key — taking it at the same time each day helps maintain stable drug levels in your blood and ensures consistent blood pressure and heart rate control throughout the 24-hour dosing period. If you miss a dose, take it as soon as you remember, but if it is close to the time for your next dose, skip the missed one and continue your usual schedule. Never take two doses at once.
References
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet. 1999;353(9146):9-13. doi:10.1016/S0140-6736(98)11181-9
- Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426-2435.
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627-3639.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2023.
- British National Formulary (BNF). Bisoprolol fumarate. Joint Formulary Committee. Updated 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023.
- European Medicines Agency (EMA). Summary of Product Characteristics: Bisoprolol fumarate.
- Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews. 2017;1(1):CD002003.
Editorial Team
Medical Author
iMedic Medical Editorial Team – Specialists in cardiology and clinical pharmacology
Medical Reviewer
iMedic Medical Review Board – Independent panel of board-certified physicians
Evidence Framework
GRADE methodology – Level 1A evidence from systematic reviews and RCTs
Guideline Adherence
ESC 2023, AHA/ACC 2024, NICE, BNF, WHO Essential Medicines List
All content on iMedic is created by licensed medical professionals and reviewed according to international clinical guidelines. We maintain strict editorial independence with no pharmaceutical company sponsorship or advertising. For more information, visit our Editorial Standards page.